South Rampart Pharma, a US-based clinical-stage life science company that said it is advancing innovative medications for the treatment of pain and fever, announced on Tuesday that it has named Josh Blacher as its new chief financial officer.
In the new role, Blacher will be responsible for the firm's finance and accounting department, and for introducing a robust corporate development effort.
Blacher has more than twenty years of leadership experience in senior positions in the healthcare and capital markets sectors. He helped build and handle Teva Innovative Ventures. He has held the position of CFO/CBO at three publicly traded biotechnology companies, the most recent of which was Inmed Pharmaceuticals. He has served in senior positions in portfolio management at Deutsche Asset Management and equity research at Morgan Stanley and in mergers & acquisitions at Lehman Brothers.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval